Runs a Hyperliquid validator and offers HYPE-based on-chain services to HYPE holders and clients; also develops ophthalmic delivery technology.
10-K for FY2025, filed Mar 30, 2026Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE…View ↗
The Company currently stakes a majority of its HYPE tokens as part of its broader participation in the Hyperliquid ecosystem. Under its…View ↗
Hyperion DeFi operates a dedicated validator node on Hyperliquid in partnership with Kinetiq and Pier Two, under its Kinetiq x Hyperion…View ↗
The company earns HYPE rewards and commissions when its validator successfully validates blocks or transactions, and charges clients for temporary HYPE use, with fees based mainly on trading activity or other use.
10-K for FY2025, filed Mar 30, 2026We jointly operate a validator node on the Hyperliquid blockchain network and earn HYPE as rewards and commission income for validating…View ↗
We recognize revenue by applying the guidance in ASC 606, Revenue from Contracts with Customers (“ASC 606”). HYPE earned from validator…View ↗
We also enter into arrangements with customers under which we provide the temporary use of our HYPE tokens in exchange for consideration.…View ↗
10-K for FY2025, filed Mar 30, 2026
FY2025 revenue by reportable segment ↗$813.5K
10-K for FY2025, filed Mar 30, 2026
$813.5K ↗| Segment | Share | Revenue | How money arrives |
|---|---|---|---|
|
Ophthalmic Technology
Sold outright
|
1.8% |
Ophthalmic Technology, FY2025
$14.7K Sources
|
Sold outright |
|
Digital Assets
Usage-based
10-K for FY2025, filed Mar 30, 2026 |
98% |
Digital Assets, FY2025
$798.7K Sources
|
Usage-based |
HYPE holders can delegate to its validator, while clients use HYPE through temporary-use arrangements; ophthalmic products are sold to customers.
10-K for FY2025, filed Mar 30, 2026Hyperion DeFi operates a dedicated validator node on Hyperliquid in partnership with Kinetiq and Pier Two, under its Kinetiq x Hyperion…View ↗
We also enter into arrangements with customers under which we provide the temporary use of our HYPE tokens in exchange for consideration.…View ↗
Revenue is earned from the sale of our ophthalmological products. However, we have ceased our sales efforts with respect to our…View ↗
No. It lost $45.3M in FY2025.
10-Q for Q3 FY2026, filed Nov 13, 2026
Open tableView ↗
8-K, filed Aug 12, 2026
Sale of Remaining Legacy Life Sciences IP to Arctic Vision Executed in July 2026View ↗
8-K, filed Jun 5, 2026
On May 18, 2026, Native Markets informed the Company that it is terminating the Temporary Use Agreement between Native Markets and the…View ↗
8-K, filed May 14, 2026
Company Raises Adjusted Gross Profit(1) 2026 FY Guidance by ~20%View ↗
Shrinking. Revenue fell 94% in 4 years, from $14M in FY2021 to $813.5K in FY2025, about 51% a year.
Shift toward digital assets
The older report focused on developing Optejet-based eye therapies and licensing them to partners. The latest report centers on a HYPE treasury, validator operations and on-chain services, alongside ophthalmic development.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026Hyperion DeFi, Inc. is the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid’s native token, HYPE…View ↗
The Company currently stakes a majority of its HYPE tokens as part of its broader participation in the Hyperliquid ecosystem. Under its…View ↗
Hyperion DeFi operates a dedicated validator node on Hyperliquid in partnership with Kinetiq and Pier Two, under its Kinetiq x Hyperion…View ↗
Ophthalmic sales scaled back
The older report planned to develop and commercialize ophthalmic products itself or with partners; the latest report says it ceased ophthalmic sales efforts but continues Optejet development and registration.
10-K for FY2022, filed Mar 31, 2023 10-K for FY2025, filed Mar 30, 2026Our goal is to become a leading developer and provider of advanced ophthalmic therapies based upon our microdose array print (MAP) platform…View ↗
Loading...